Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy

Clinical trial NCT05352828 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05352828
Sponsor: Tessa Therapeutics
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Classical Hodgkin Lymphoma Hodgkin Disease Refractory Hodgkin Disease Recurrent

Start date: 2022-07-25
Primary completion: 2025-12-15
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.